CBD crystal resistant distillate for high-minor, flowable formulations.

CBD CRD from Cilo Cybin's GMP cannabinoid API portfolio: 43-58% CBD with 15%+ minor cannabinoids, free-flowing amber oil, and formulation-ready documentation.

This page provides supporting information about Cilo Cybin's company platform, products, services, and stakeholder communications.

A CBD distillate designed to resist crystallisation while maintaining a diversified minor cannabinoid profile for easier formulation.

CBD CRD is a crystal resistant distillate designed for formulations where flowability, viscosity control, and reduced crystallisation risk are important. The target profile is 43-58% CBD with ≥15% minor cannabinoids and a ≤0.3% THC target, creating a CBD-led oil input with more profile breadth than CBD Isolate .

This format is useful where high CBD powder inputs may create crystallisation or handling challenges. Product teams can use CBD CRD in oil-soluble systems such as tinctures, topical products, edible systems, and vape formats where permitted, while validating carrier compatibility, clarity, viscosity, and stability-study outcomes.

Use these pages to move between adjacent products without losing the family context.

Send the Cilo Cybin team your target format, desired specification, estimated volume, destination market, and documentation requirements.

Pharmaceutical biotechnology for regulated cannabinoid API's, bulk products, finished formats, and partner supply programs.

For partnership, product, or company enquiries, contact Cilo Cybin for the latest approved information.